Andrew Campbell, MD
Family Medicine · Plainfield, INNPI 1871798793
Payments from drug & device makers
Across 304 payments — averaging $14.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$669
- AbbVie$590
- Novo Nordisk$503
- Lilly USA, LLC$316
- Pfizer$293
- GSK$263
- plus $2K from 33 others
Across 1 payment — averaging $1250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$1K
What the payments were for
- Food & beverage$4,442100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $669 |
| AbbVie(2 entities) | 56 | $590 |
| Novo Nordisk | 36 | $503 |
| Lilly USA, LLC | 22 | $316 |
| Pfizer | 24 | $293 |
| GSK | 21 | $263 |
| Sanofi-aventis U.S. LLC | 7 | $148 |
| Exact Sciences | 8 | $144 |
| Johnson & Johnson | 6 | $135 |
| Astellas Pharma US Inc | 7 | $134 |
| Heartflow, Inc. | 6 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $106 |
| Amgen | 5 | $91 |
| Dexcom, Inc. | 5 | $84 |
| Eisai Inc. | 4 | $76 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Antares Pharma, Inc. | 5 | $72 |
| Amarin Pharma, Inc. | 4 | $59 |
| Ultragenyx Pharmaceutical Inc. | 3 | $57 |
| Novartis | 3 | $54 |
| Merck | 4 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $45 |
| Daiichi Sankyo Inc. | 3 | $43 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Mylan Specialty L.p. | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Medline Industries LP | 1 | $28 |
| Axonics, Inc. | 1 | $24 |
| Nalpropion Pharmaceuticals LLC | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Nevro Corp. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Circassia Inc. | 1 | $12 |
| Adlon Therapeutics L.p. | 1 | $11 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$4,460 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $144,054 |
| MounjaroTirzepatide | 102 | $115,351 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $70,350 |
| FarxigaDapagliflozin Propanediol | 43 | $60,885 |
| EliquisApixaban | 43 | $49,389 |
| JardianceEmpagliflozin | 41 | $42,938 |
| XareltoRivaroxaban | 26 | $34,994 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $31,519 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $19,429 |
| TrulicityDulaglutide | 14 | $13,467 |
| LinzessLinaclotide | 16 | $12,929 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 42 | $12,642 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,362 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 50 | $11,016 |
| BelsomraSuvorexant | 16 | $9,742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $503 | $144,054101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta, Shingrix | $263 | $137,889241 claims |
| Lilly USA, LLCMounjaro, Trulicity | $316 | $128,818116 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $669 | $70,15255 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $35 | $51,16552 claims |
| PfizerEliquis | $293 | $49,38943 claims |
| Johnson & JohnsonXarelto | $135 | $34,99426 claims |
| AbbVieLinzess, Synthroid | $590 | $14,78038 claims |
| MerckBelsomra | $48 | $9,74216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Plainfield
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.